Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), point decrease (Expand Search), note decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1981
-
1982
-
1983
Decreased s.c. growth of CNDT 2.5 cells after systemic administration of DOPC liposome-conjugated siNRP-2.
Published 2013“…NRP-2-siRNA DOPC-treatment led to a significant decrease in tumor growth compared with cntr siRNA DOPC-treatment (264.4 mm<sup>3</sup> vs. 751.3 mm<sup>3</sup>, respectively; *<i>p</i> = 0.01). …”
-
1984
-
1985
-
1986
LA decreases infarct size in rats subjected to I/R injury.
Published 2013“…<p>Representative illustrations of infarct size as stained by Evans Blue and TTC (a). LA decreased infarct size compared with I/R+V group and wortmannin pretreated group (b). …”
-
1987
-
1988
LA decreases cardiomyocyte apoptosis in rats subjected to MI/R injury.
Published 2013“…<p>Representative photomicrograph showed that TUNEL-positive cardiomyocytes were more frequently observed in I/R+V group and the wortmannin-pretreated group compared with the LA group (a). …”
-
1989
-
1990
-
1991
-
1992
-
1993
-
1994
Hepatic irradiation decreases the proportion of DX5<sup>–</sup>TRAIL<sup>+</sup> lrNK cells for up to two months.
Published 2018“…<p>(A) The liver and splenic lymphocytes were stained with anti-NK1.1, anti-TCRβ, and PI. …”
-
1995
-
1996
Decreased splicing efficiency in DENV infected cells.
Published 2016“…<p>(A) Schematic representation of splicing analysis. …”
-
1997
-
1998
-
1999
S5 Raw image -
Published 2024“…Through the presence of an inclusion complex, a higher aqueous dispersion (65-fold) resulting in a higher drug content and an elevated release profile was achieved. …”
-
2000